The association of XRCC1 gene single nucleotide polymorphisms with response to neoadjuvant chemotherapy in locally advanced cervical carcinoma

Journal of Experimental and Clinical Cancer Research

Volumn 28, Issue 1, 2009, Pages

  Cheng, Xiao Dong ^a   Lu, Wei Guo ^a   Ye, Feng ^a   Wan, Xiao Yun ^a   Xie, Xing ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC METAL COMPLEX; ARGININE; BLEOMYCIN; CISPLATIN; IFOSFAMIDE; PACLITAXEL; VINDESINE; XRCC1 PROTEIN; ANTINEOPLASTIC AGENT; DNA BINDING PROTEIN; X-RAY REPAIR CROSS COMPLEMENTING PROTEIN 1;

ADJUVANT CHEMOTHERAPY; ALLELE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CODON; DRUG TREATMENT FAILURE; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; UTERINE CERVIX CARCINOMA; ADJUVANT THERAPY; ENZYME IMMUNOASSAY; GENETICS; METABOLISM; UTERINE CERVIX TUMOR;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DNA-BINDING PROTEINS; FEMALE; GENOTYPE; HUMANS; IMMUNOENZYME TECHNIQUES; NEOADJUVANT THERAPY; POLYMORPHISM, SINGLE NUCLEOTIDE; UTERINE CERVICAL NEOPLASMS;

EID: 68249162551     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-28-91     Document Type: Article

References (21)

1. Results of a prospective randomized trial with neoadjuvant chemotherapy in stage B bulky squamous carcinoma of the cervix. J Sardi C Sananes A Giaroli J Bayo NG Rueda S Vighi N Guardado G Paniceres L Snaidas C Vico, Gynecol oncol 1993 49 156 165 10.1006/gyno.1993.1100 7684993 (Pubitemid 23169984)
2. Neoadjuvant chemotherapy followed by radical surgery and radiotherapy vs pelvic irradiation in patients with cervical cancer FIGO stage IIB-IVA. Y Kornovski G Gorehev, BUON 2006 11 291 297
3. Prognostic factors in patients with bulky stage B or A cervical carcinoma undergoing neoadjuvant chemotherapy and radical hysterectomy. CH Lai S Hsueh TC Chang CJ Tseng KG Huang HH Chou SM Chen MF Chang HC Shum, Gyneol oncol 1997 64 456 462 10.1006/gyno.1996.4603 (Pubitemid 27120436)
4. Mechanisms of resistance to cisplatin. M Kartalon JM Essigmann, Mutation Res 2001 478 23 43 11406167
5. Which gene is a domonant predicator of response during FOLFOX chemotherapy for the treatment of metastatic colorectai cancer, the MTH FR or XRCC1 gene. KW Suh JH Kim Y Kim YB Kim C Lee S Choi, Ann Surg Oncol 2006 13 1379 1385 10.1245/s10434-006-9112-y 17009149
6. Quality control by DNA repair. T Lindahl RD Wood, Science 1999 286 1897 1905 10.1126/science.286.5446.1897 10583946
7. Polymorphisms in the DNA repair genes XRCC1 and ERCC2 and biomarkers of DNA damage in human blood monounclear cells. EJ Duell JK Wiencke TJ Cheng A Varkonyi ZF Zuo TD Ashok EJ Mark JC Wain DC Christiani KT Kelsey, Carcinogenesis 2000 21 965 971 10.1093/carcin/21.5.965 10783319
8. A polymorphism of the XRCC1 gene predicts for response to platinum based treatment in advanced colorectal cancer. J Stoehlmacher V Ghaderi S Iobal S Groshen D Tsao-Wei D Park HJ Lenz, Anticancer Res 2001 21 3075 3079 11712813
9. XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treatment with platinum chemotherapy. S Gurubhagavatula G Liu S Park W Zhou L Su JC Wain TJ Lynch DS Neuberg DC Christiani, J Clin Oncol 2004 22 2594 2601 10.1200/JCO.2004.08.067 15173214 (Pubitemid 41103746)
10. XRCC1 R399Q polymorphism is associated with response to platimun-based neoadjuvant chemotherapy in bulky cervical cancer. HH Chung MK Kim JW Kim NH Park YS Song SB Kang HP Lee, Gynecol Oncol 2006 103 1031 1037 10.1016/j.ygyno.2006.06.016 16875718 (Pubitemid 44821330)
11. XRCC1 Arginine194Tryptophan and GGH-401Cytosine/Thymine polymorphisms are associated with response to platinum-based neoadjuvant chemotherapy in cervical cancer. K Kim SB Kang HH Chung JW Kim NH Park YS Song, Gynecol Oncol 2008 111 509 515 10.1016/j.ygyno.2008.08.034 18851872
12. Association between polymorphisms of RECC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy. JS Ryu YC Hong HS Han JE Lee S Kim YM Park YC Kim TS Hwang, Lung Cancer 2004 44 311 316 10.1016/j.lungcan.2003.11.019 15140544 (Pubitemid 38609439)
13. The single nucleotide polymorphisms and the sensitivity of platinum-based chemotherapy in non-small lung cancer. ZH Wang XP Liao W Tan, CJC 2004 23 865 868
14. DNA repair gene XRCC1 polymorphisms and the senstivity of chemotherapy in advanced stage lung cancer. MQ Shi CM Gao JZ Wu, Chin Clin Oncology 2006 11 575 578
15. An association of polymorphisms of DNA repair genes XRCC1 and XRCC3 with colorectal cancer. R Krupa J Blasiak, J Exp Clin Cancer Res 2004 23 285 294 15354414
16. Reduced DNA repair capacity in laryngeal cancer subjects: A comparison of phenotypic and genotypic results. M Gajecka M Rydzanicz R Jaskula-Sztul M Wierzbicka W Szyfter K Szyfter, Adv Otorhinolaryngol 2005 62 25 37 15608415
17. Genetic polymorphisms in DNA base-excision repair genes ADPRT, XRCC1, and APE1 and the risk of squamous cell carcinoma of the head and neck. C Li Z Hu J Lu Z Liu LE Wang AK El-Naggar EM Sturgis MR Spitz Q Wei, Cancer 2007 110 867 875 10.1002/cncr.22861 17614107 (Pubitemid 47257666)
18. Polymorphysims in genes of nucleotide and base excision repair: risk and prognosis of colorectal cancer. V Moreno F Gemignani S Landi L Gioia-Patricola A Chabrier I Blanco S González E Guino G Capell F Canzian, Clin Cancer Res 2006 12 2101 2108 10.1158/1078-0432.CCR-05-1363 16609022
19. Influence of DNA repair gene polymorphisms on the yield of chromosomal aberrations. A Kiuru C Lindholm I Heilimo M Ceppi A Koivistoinen T Ilus A Hirvonen H Norppa S Salomaa, Environ Mol Mutagen 2005 46 198 205 10.1002/em.20155 15971256 (Pubitemid 41642312)
20. Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy. E Reed, Cancer Treat Rev 1998 24 331 344 10.1016/S0305-7372(98)90056-1 9861196
21. Increase mRNA levels of xeroderma pigmentosum complementation group B(XPD) and cockayne's syndrome complementation group B (CSB) without increased mRNA level of multidrug-resistance geng (MDR1) or metallothionein-II(MT-II) in platinum-resistant human ovarian cancer tissue. M Dabholkar K Thornton J Vionnet F Bostick-Bruton JJ Yu E Reed, Biochem Pharmacol 2000 60 1611 1619 10.1016/S0006-2952(00)00448-2 11077043 (Pubitemid 30834112)